Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate - PubMed (original) (raw)

Practice Guideline

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate

Kathryn M Curtis et al. MMWR Morb Mortal Wkly Rep. 2021.

Abstract

U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR), adapted by CDC from global guidance developed by the World Health Organization (WHO), provides evidence-based guidance on contraceptive use for U.S. health care providers (1). During January-February, 2021, CDC evaluated the 2019 WHO recommendation on self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) (2). CDC adopted the WHO recommendation on the basis of moderate-certainty evidence that self-administered DMPA-SC is safe and effective, and has higher continuation rates compared with provider-administered DMPA. The new U.S. SPR recommendation states that self-administered DMPA-SC should be made available as an additional approach to deliver injectable contraception. Provider-administered DMPA should remain available. Self-administered DMPA-SC is a user-controlled method that has the potential to improve contraceptive access and increase reproductive autonomy. Self-administered DMPA-SC should be offered in a noncoercive manner through a shared decision-making process between patients and their health care providers, with a focus on patient preferences and equitable access to the full range of contraceptive methods.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No other potential conflicts of interest were disclosed.

Cited by

U.S. Selected Practice Recommendations for Contraceptive Use, 2024.
Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K, Kortsmit K, Cohen MA, Whiteman MK; Contributors. Curtis KM, et al. MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1. MMWR Recomm Rep. 2024. PMID: 39106301 Free PMC article.
Provision of DMPA-SC for self-administration in different practice settings during the COVID-19 pandemic: Data from providers across the United States.
Comfort AB, Alvarez A, Goodman S, Upadhyay U, Mengesha B, Karlin J, Shokat M, Blum M, Harper CC. Comfort AB, et al. Contraception. 2024 Mar;131:110360. doi: 10.1016/j.contraception.2023.110360. Epub 2023 Dec 27. Contraception. 2024. PMID: 38158075 Free PMC article.
Assessing differences in contraceptive provision through telemedicine among reproductive health providers during the COVID-19 pandemic in the United States.
Comfort AB, Rao L, Goodman S, Raine-Bennett T, Barney A, Mengesha B, Harper CC. Comfort AB, et al. Reprod Health. 2022 Apr 22;19(1):99. doi: 10.1186/s12978-022-01388-9. Reprod Health. 2022. PMID: 35459218 Free PMC article.
Single-Visit Long-Acting Reversible Contraception Initiation Among Adolescents Before and During COVID-19.
Allison BA, Yates L, Tadikonda A, Arora KS, Stuart GS. Allison BA, et al. J Adolesc Health. 2024 Feb;74(2):367-374. doi: 10.1016/j.jadohealth.2023.08.031. Epub 2023 Oct 9. J Adolesc Health. 2024. PMID: 37815761
Contraception Recommendations: Updates for the Busy Clinician.
Clark EA, Curtis KM. Clark EA, et al. Am Fam Physician. 2022 Sep;106(3):227-228. Am Fam Physician. 2022. PMID: 36126000 Free PMC article. No abstract available.

References

1. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-4). 10.15585/mmwr.rr6504a1 - DOI - PubMed
1. World Health Organization. WHO consolidated guidance on self-care interventions for health: sexual and reproductive health and rights. Geneva, Switzerland: World Health Organization 2019. - PubMed
1. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3). 10.15585/mmwr.rr6503a1 - DOI - PubMed
1. Kennedy CE, Yeh PT, Gaffield ML, Brady M, Narasimhan M. Self-administration of injectable contraception: a systematic review and meta-analysis. BMJ Glob Health 2019;4:e001350. 10.1136/bmjgh-2018-001350 - DOI - PMC - PubMed
1. Holt K, Reed R, Crear-Perry J, Scott C, Wulf S, Dehlendorf C. Beyond same-day long-acting reversible contraceptive access: a person-centered framework for advancing high-quality, equitable contraceptive care. Am J Obstet Gynecol 2020;222:S878.e1-S878.e6. 10.1016/j.ajog.2019.11.1279 - DOI - PubMed

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate - PubMed (original) (raw)